An announcement from Reviva Pharmaceuticals Holdings ( (RVPH) ) is now available.
Reviva Pharmaceuticals announced an enrollment update for its open-label extension study on brilaroxazine, showcasing promising results in schizophrenia patients. With 108 patients completing a year of treatment, the trial indicates good tolerability and supports the drug’s New Drug Application submission to the FDA. The study is on track to provide crucial long-term safety data by early 2025, with top-line results expected by December 2024.
See more data about RVPH stock on TipRanks’ Stock Analysis page.
